Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Anlotinib Hydrochloride: Multi-Target TKI for Angiogenesis A

    2026-06-07

    Anlotinib Hydrochloride: Multi-Target TKI for Angiogenesis Assays

    Principle and Experimental Rationale

    Anlotinib hydrochloride is a novel small-molecule multi-target tyrosine kinase inhibitor (TKI) with potent anti-angiogenic and anti-proliferative activity. By selectively inhibiting key receptor tyrosine kinases—VEGFR2, PDGFRβ, and FGFR1—anlotinib blocks critical signaling events that drive angiogenesis and tumor growth. Its mechanism of action centers on preventing phosphorylation of these receptors and suppressing downstream ERK signaling, as evidenced in both cellular and in vivo models (reference study). Unlike earlier-generation TKIs, anlotinib demonstrates superior selectivity and potency, enabling robust inhibition of endothelial cell migration and capillary tube formation at nanomolar concentrations, while exhibiting minimal cytotoxicity up to 1 μM. These characteristics make it especially well-suited for functional angiogenesis assays and tumor microenvironment research.

    Stepwise Experimental Workflow: Capillary Tube Formation and Migration Assays

    Researchers investigating tumor angiogenesis and anti-angiogenic therapies frequently turn to in vitro models such as endothelial cell migration inhibition and capillary tube formation assays. Anlotinib hydrochloride, available from APExBIO, supports optimized experimental workflows due to its high specificity and low toxicity profile.

    Protocol Parameters

    • Compound dilution: Prepare anlotinib hydrochloride in DMSO and further dilute in assay medium to final concentrations ranging from 0.1 nM to 1 μM; ensure DMSO content does not exceed 0.1% (v/v).
    • Cell seeding density: For tube formation, seed EA.hy 926 or HUVEC cells at 1.5–2.0 × 104 cells per well in a 96-well plate pre-coated with 50 μL Matrigel (kept at 4°C prior to use).
    • Treatment regimen: Add anlotinib 30 minutes before stimulation with angiogenic growth factors (e.g., VEGF at 20 ng/mL, PDGF-BB at 10 ng/mL, FGF-2 at 10 ng/mL), then incubate for 6–18 hours at 37°C with 5% CO₂.

    Key Innovation from the Reference Study

    The reference study delivered a pivotal advance by characterizing anlotinib as a highly potent and selective VEGFR2 inhibitor, with an IC50 value of less than 1 nM in cell-based assays. This selectivity is critical not only for maximizing anti-angiogenic effects but also for minimizing off-target toxicity—a common limitation of earlier TKIs. Translating this into practical research, the study's methodology supports the use of anlotinib in functional assays where low nanomolar concentrations suffice to suppress endothelial migration and tube formation, while enabling simultaneous assessment of ERK signaling inhibition. For example, in HUVECs and EA.hy 926 cells, anlotinib consistently outperformed sunitinib and sorafenib by achieving higher inhibition of tube formation at lower doses, thus offering a robust platform for dissecting angiogenic pathways and screening combinatorial therapies.

    Advanced Applications and Comparative Advantages

    Integrating anlotinib hydrochloride into cancer research workflows unlocks several strategic advantages:

    • Superior anti-angiogenic potency: Anlotinib achieves nanomolar inhibition of VEGFR2, PDGFRβ, and FGFR1, with IC50 values of 5.6 ± 1.2 nM, 8.7 ± 3.4 nM, and 11.7 ± 4.1 nM, respectively (product information), translating to more pronounced suppression of endothelial cell migration and capillary tube formation than reference TKIs.
    • Low cytotoxicity window: No significant cytotoxic effects are observed up to 1 μM, allowing functional assays to be conducted without confounding cell death, as confirmed in EA.hy 926 and HUVEC lines (complementary article).
    • Oral bioavailability and tissue penetration: Preclinical PK studies demonstrate favorable oral bioavailability (up to 77% in dogs) and extensive tissue distribution, including blood-brain barrier penetration, providing translational value for in vivo tumor models.
    • Workflow versatility: The selective inhibition of the ERK signaling pathway and the ability to block multiple angiogenic receptors make anlotinib suitable for primary screening, mechanistic studies, and co-treatment protocols in cancer research.

    Compared to established agents such as sunitinib, sorafenib, and nintedanib, anlotinib offers broader and more robust in vivo antitumor efficacy, sometimes leading to tumor regression in mouse models (extension article). This positions anlotinib as a next-generation agent for dissecting angiogenesis in both basic and translational oncology settings.

    Troubleshooting and Optimization Tips

    To maximize assay reproducibility and data quality when using anlotinib hydrochloride, consider the following troubleshooting strategies:

    • Solubility and compound handling: Dissolve the lyophilized compound first in 100% DMSO to create a 10 mM stock. Avoid repeated freeze-thaw cycles; aliquot and store at -20°C as recommended by APExBIO.
    • DMSO controls: Always include vehicle-only controls at the highest DMSO concentration used in experimental wells to rule out solvent effects on endothelial morphology or migration.
    • Cell health monitoring: Confirm lack of cytotoxicity via viability assays (e.g., MTT or CellTiter-Glo) especially at higher anlotinib concentrations or with prolonged incubation (>18 hours).
    • Signal pathway validation: To verify ERK pathway inhibition, perform parallel Western blots for phospho-ERK (Thr202/Tyr204) and phospho-VEGFR2 (Tyr1175) after 30–60 min treatment with anlotinib at 10 nM–1 μM.
    • Growth factor stimulation timing: Pre-incubate cells with anlotinib for 30 minutes before adding VEGF, PDGF-BB, or FGF-2 to ensure effective receptor blockade.

    For more troubleshooting approaches and protocol variations, the workflow guide in this detailed article provides additional optimization strategies and comparative benchmarks.

    Interlinking with Related Research

    Several recent articles complement the practical application of anlotinib hydrochloride:

    Future Outlook: Implications for Cancer Research

    The robust anti-angiogenic efficacy, selectivity, and favorable safety profile of anlotinib hydrochloride signal a new era for mechanistic and translational cancer research. By enabling precise modulation of endothelial cell migration and capillary tube formation—core processes in tumor vascularization—anlotinib empowers researchers to dissect the interplay of growth factor signaling with unprecedented specificity. As Anlotinib hydrochloride continues to be evaluated in preclinical and emerging clinical contexts, its utility is expected to expand into combinatorial therapy models, resistance mechanism studies, and high-content screening platforms. The already-demonstrated capacity to outperform legacy TKIs in both in vitro and in vivo settings underscores its value as a benchmark compound for next-generation anti-angiogenic research. Ongoing work will clarify optimal dosing regimens, resistance signatures, and synergy with immunotherapies—positioning anlotinib as a cornerstone for future oncology breakthroughs.